



MARCH 10, 2015 | MIAMI, FL

Cautionary Statement Regarding Forward Looking Statements

This presentation contains forward-looking statements including with respect to estimated 2015 guidance and the impact of various factors on operating results. Each of the forward-looking statements is subject to change based on various important factors, including without limitation, competitive actions in the marketplace, adverse actions of governmental and other third-party payers and the results from the Company's acquisition of Covance. Actual results could differ materially from those suggested by these forward-looking statements. Further information on potential factors that could affect LabCorp's operating and financial results is included in the Company's Form 10-K for the year ended December 31, 2014, including in each case under the heading risk factors, and in the SEC. The information in this press release should be read in conjunction with a review of the Company's filings with the SEC including the information in the section of the Company's Form 10-K for the year ended December 31, 2014, and subsequent Forms 10-Q, under the heading MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.



INTRODUCTION TO LABCORP

Leading National Clinical Laboratory

- >\$6B in revenue in 2014
- \$60B US Clinical Laboratory market
- >36,000 employees worldwide
- National network of 37 primary laboratories and 1,750 patient service centers



- Offers broad range of 4,500+ clinical, anatomic pathology, genetic and genomic tests
- **Processes** ~500,000 patient specimens daily
- Serves >220,000 physicians, government agencies, managed care organizations, hospitals, clinical labs and pharmaceutical companies
- Comprehensive logistics and IT connectivity capabilities



CREATING THE WORLD'S LEADING HEALTHCARE DIAGNOSTICS COMPANY

 Acquisition of Covance Valuation: Approximately \$5.7 billion, net of cash acquired Financing: Approximately \$3.9 billion in long-term debt Timing: Closed February 19, 2015 		solutions made REAL* Solutions MADE REAL* g-term debt
--	--	---

Growth: New value for pharma, payers, providers, and consumers

The merger with Covance creates value and delivers sustained profitable growth



INTRODUCTION TO COVANCE

Leading CRO & Drug Development Services Provider

- >\$2.5B in revenue last year
- Serves \$140 billion global pharmaceutical R&D market SOLUTIONS MADE REAL[®]
- Only provider of full spectrum of drug development services
 - Involved in the development of all of the top 50 drugs on the market
 - #1 in central laboratory / preclinical services
 - ~\$900M revenue in Phase I-IV clinical trial management services
- Generates more safety and efficacy data than any other CRO
- Market leader in nutritional chemistry and food safety testing
- >12,500+ employees worldwide
- Global network of operations in 30+ countries with trial activity in over 100 countries





TRANSFORMATIVE COMBINATION: CREATING THE WORLD'S LEADING HEALTHCARE DIAGNOSTICS COMPANY

Powerful combination of personnel, assets, and capabilities

Strong management teams

Breadth of relationships (physicians, pharma, consumers, payers, hospitals, etc.)

Scientific, bioinformatics and analytics expertise

Complementary datasets

Commercial infrastructure and global footprint

Physician and consumer access and connectivity


Continued innovation and targeted investment

Industry growth

Trends favor high quality, efficient providers that deliver better outcomes at lower cost



COMBINATION CREATES THE BEST END-TO-END PARTNER FOR PHARMACEUTICAL AND BIOTECH DEVELOPMENT



Strong position



I A BOORD WILL BE THE PARTNER OF CHOICE FOR BODH ARMA AND IMPROVE THE LIVES OF PATIENTS

- Faster, higher quality clinical trials at lower cost
- Increased sales during patent lifetime
- Expedited commercialization of companion diagnostics
- Data analytics reduce safety recalls
- Biopharma • Improve people's health
 - Drive profitable growth
- Constitues Create shareholder Pavers

LabCorp

- Greater access to clinical trials for patients
- Data & analytics drive increased confidence in prescriptions for: Proutore.
 - ... the right drug...
 - ...the right patient...
 - ... the right time

More personalized medicines

- Extended life and improved quality of life
- Greater access to and transparency regarding clinical trials

Improved patient outcomes at lower cost

- Fewer failures of therapy
- Data & analytics to inform prescribing decisions
- Reduced hospitalization costs

2015 AND 2016 PRIORITIES

Continue core business initiatives (Business process re-engineering, BeaconLBS, Enlighten Health)


Unify organizations

Capitalize on the enhanced capabilities of our combined lab organizations

Deliver synergies (\$100M annual cost reduction by 2017) Fully deploy top three value creation opportunities



COMBINATION PROVIDES SIGNIFICANT NEW GROWTH AVENUES





DETAIL ON THE TOP THREE OPPORTUNITIES

Incremental 2018 Revenue

>\$150M

Partner of choice to develop and commercialize companion diagnostics

Enhance Phase IV trial

experience and

Deliver faster clinical

trial enrollment

>\$100M

>\$50M post-market surveillance

TOP THREE VALUE CREATORS TO BRING TO MARKET IN 2016

2

Deliver faster clinical trial enrollment


Partner of choice to develop and commercialize companion diagnostics

³ Enhance Phase IV trial experience and post-market surveillance




ACQUISITION ALLOWS US TO IDENTIFY AND TARGET PATIENT POPULATIONS WITH SPECIFIC DISEASE CONDITIONS

Example: Non-small cell lung cancer with EGFR+ mutation



Now: Leveraging LabCorp database for (1) patient locations & (2) viable sites



1. NCI-designated cancer centers. Estimated number of patients based on average number of patients in an oncology Phase III trial and average number of sites. 2. South Florida Business Journal, 2014 – Top 25 centers in South Florida with ~1000-6000 patients per center



COMBINED COMPANY HAS THE OPPORTUNITY TO BENEFIT FROM CRO MARKET EXPANSION AND AN INCREASE IN SHARE

	2014	2016	2018	
Biopharma spend on Phase II-III trials ¹	\$30B	\$32B	\$34B	Phase II-III trial market growing
CRO served Phase II-III trial spend (% served by CROs) ¹	\$12B (40%)	\$13B (42%)	\$15B (44%)	CRO revenue capture increasing
Combined company revenue for Phase II-III	\$750M (~6%)	~850M (~6-7%)	~\$1B (~6-7%)	Maintain current growth trend
trials (% share) ²		\$900M+ (~7%)	\$1.1B+ (~7-8%)	Combined company poised to increase Phase III share
		\$50M+ increase	\$150M+ increase	
		Equivalent to winning ~1-2 incremental Phase III trials per year ³		

1. Covance market research; Numbers rounded to the nearest \$1B 2. Numbers rounded to the nearest \$50M 3. Assumes average Phase III trial cost of \$75M and that CRO served revenue per trial varies between 30-60% of total cost, amortized over a period of 3 years (approximate length of a Phase III trial) Note: Numbers may not sum due to rounding. Source: Covance market research



TOP THREE VALUE CREATORS TO BRING TO MARKET IN 2016


Deliver faster clinical trial enrollment

Partner of choice to develop and commercialize companion diagnostics

Enhance Phase IV trial experience and post-market surveillance



COMBINED COMPANY WILL DRIVE CRO SHARE GAIN FOR DRUG TRIALS REQUIRING CD_x PROGRAMS



Early stage services strength followed by seamless execution of CDx will boost share of clinical trials



COMPANION DIAGNOSTICS CAPABILITIES ADD >\$100M REVENUE BY 2018

Sources of new value for combined company	2018 added opportunity	Revenue generator	Key figures for estimate
Biomarker & central lab testing	\$60M+	50-200 added biomarker development and testing contracts per year	\$1.8M total downstream testing revenue per biomarker contract ¹
CDx development services	\$40M+	~30 new CDx partner opportunities now; ~\$240M potential annual revenue ²	15-40% of potential revenue captured; 10% CAGR to 2018 ³
Early-Phase clinical trials share	\$30M+	1-2 incremental Phase II trials won per year by 2018 ⁴	\$30M revenue per Phase II trial ⁵



TOP THREE VALUE CREATORS TO BRING TO MARKET IN 2016

Deliver faster clinical trial enrollment

Partner of choice to develop and commercialize companion diagnostics

Enhance Phase IV trial experience and post-market surveillance



UNMET NEEDS ADDRESSED BY COMBINED COMPANY'S ENHANCED PHASE IV PATIENT EXPERIENCE AND POST-MARKET SURVEILLANCE

Combined company positioned to deliver superior Phase IV trial experience




1,750 LabCorp patient service centers and ~5,000 phlebotomists in physician offices make testing more convenient



LabCorp patient web portal eliminates scheduling hassle

12 Billion test results and 70M+ unique patients enable Post-market surveillance



COMBINED COMPANY HAS OPPORTUNITY TO GROW SHARE IN PHASE IV TRIALS AND POST-MARKET SURVEILLANCE

	2014	2016	2018	
Biopharma Phase IV and post-market spend ¹	\$12B	\$13B	\$14B	Phase IV trial market growing
CRO served Phase IV / post- market spend (% served by CROs) ¹	\$5B (38%)	\$5B (39%)	\$6B (40%)	CRO revenue capture increasing
Combined company revenue for	~\$150M (~3%)	~\$180M (~4%)	~\$220M (~4%)	Maintain current growth trend
Phase IV / post-market (% share) ²		\$200M+ (~4%)	\$270M+ (~4-5%)	Combination poised to increase Phase IV/post-mkt share
		\$20M+ increase	\$50M+ increase	
	Equivalent to winning ~2-4 <u>incremental</u> <u>Phase IV / post-market trials</u> per year ³			

1. Covance market research; Numbers rounded to the nearest \$1B 2. Numbers rounded to the nearest \$10M 3. Assumes average Phase IV trial cost of \$10M and length of <1 year, and average post-market surveillance cost of \$30-40M and length of ~5 years; assumes CRO served revenue per trial varies between 30-60% of total cost (Covance market research, Parexel Biopharmaceutical Statistical Sourcebook 2014) Note: Numbers may not add up due to rounding.



COMBINED COMPANY RETAINS FINANCIAL STRENGTH

2014 Financial Review and 2015 Financial Guidance



COMBINED COMPANY RETAINS FINANCIAL STRENGTH: NO FUNDAMENTAL SHIFT IN LONG-TERM CAPITAL ALLOCATION STRATEGY

- Accretive to Adjusted EPS before synergies in Year 1; Earns cost of capital by Year 4
- Commitment to investment grade balance sheet
- Near-Term Free Cash Flow used to pay down debt and invest in fold-in acquisitions
- Share buyback program resumes as we approach 2.5x target leverage ratio

LabCorp		Covance
\$6,012	Revenue	\$2,521
\$952	Adjusted Operating Income ^{1, 2}	\$304
15.8%	Adjusted Operating Margin ^{1, 2}	12.1%
\$6.80	Adjusted EPS ³	N/A
\$739	Operating Cash Flow	\$296
\$204	Capital Expenditures	\$142
\$536	Free Cash Flow	\$154

2014 Results (\$ in Millions)

(1) LabCorp operating income adjusted to exclude restructuring and other special items of \$41.2 million. See non-GAAP reconciliation in the Appendix.

(2) Covance operating income adjusted to exclude restructuring costs, transaction related expenses and asset impairments of \$69.7 million. See non-GAAP reconciliation in the Appendix.

(3) LabCorp EPS adjusted to exclude amortization, restructuring and special items. See non-GAAP reconciliation in the Appendix.



Excluding the impact of amortization, restructuring and special items, guidance for 2015 is:

Total revenue growth:	Approximately 40% - 44% ⁽¹⁾
Clinical lab business revenue growth:	Approximately 3% - 5%
Covance business revenue growth:	Approximately 4% - 6% ⁽²⁾
Adjusted EPS:	\$7.35 - \$7.70
Operating cash flow:	\$1,075 Million - \$1,100 Million ⁽³⁾
Capital expenditures:	\$325 Million - \$350 Million
Free cash flow:	\$725 Million - \$775 Million ⁽³⁾

- (1) Revenue growth is adjusted for approximately 160 basis points of negative currency impact assuming foreign exchange rates effective as of January 31, 2015.
- (2) Revenue growth versus full year 2014 revenue, and is adjusted for approximately 330 basis points of negative currency impact assuming foreign exchange rates effective as of January 31, 2015.
- (3) Operating and free cash flow are burdened by approximately \$90 million of net non-recurring items related to the Covance acquisition.



COMBINATION CREATES THE WORLD'S LEADING HEALTHCARE DIAGNOSTICS COMPANY

- Faster, higher quality clinical trials at lower cost
- Increased sales during patent lifetime Biophaima
- Expedited commercialization of companion diagnostics
- Data analytics reduce safety recalls

- More personalized medicines
- Extended life and improved quality of life
- Greater access to and transparency regarding clinical trials


- Greater access to clinical trials for patients
- Data & analytics drive increased Providers confidence in prescriptions for:
 - ...the right drug...
 - ...the right patient...
 - …the right time

• Improve people's health • Drive profitable

LabCorp

- growth CORSTITUET Create shareholder
- Payers **Improved patient** outcomes at lower cost
 - Fewer failures of therapy
 - Data & analytics to inform prescribing decisions
 - Reduced hospitalization costs





Appendix



LabCorp Adjusted Operating Income

(In millions, except per share data)

Year En	
December 31, 2014	
\$	910.4
	17.8
	23.4
\$	951.6
	Decem

(1) During 2014, the Company recorded net restructuring and special items of \$17.8 million. The charges included \$10.6 million in severance and other personnel costs along with \$8.3 million in facility-related costs associated with facility closures and general integration initiatives. The Company reversed previously established reserves of \$0.4 million in unused severance and \$0.7 million in unused facility-related costs.

In addition to these net restructuring charges, the Company recorded \$23.4 million in consulting expenses relating to fees incurred as part of Project LaunchPad, its comprehensive enterprise-wide cost structure review, as well as legal fees associated with its Covance, Inc. and LipoScience acquisitions, and one-time CFO transition costs (all such fees are recorded in selling, general and administrative).



RECONCILIATION OF NON-GAAP FINANCIAL MEASURES

LabCorp Adjusted EPS

	Year	• Ended
Adjusted EPS Excluding Amortization	December 31, 2014	
Diluted earnings per common share	\$	5.91
Restructuring and special items ⁽¹⁾		0.34
Amortization expense ⁽²⁾		0.55
Adjusted EPS	\$	6.80

- (1) The after tax impact of the restructuring and other special charges decreased net earnings for the year ended December 31, 2014, by \$29.1 million and diluted earnings per share by \$0.34 (\$29.1 million divided by 86.4 million shares).
- (2) The Company continues to grow the business through acquisitions and uses Adjusted EPS (excluding restructuring, special items and amortization) as a measure of operational performance, growth and shareholder returns. The Company believes adjusting EPS for these items provides investors with better insight into the operating performance of the business. For the year ended December 31, 2014, intangible amortization was \$76.7 million (\$47.3 million net of tax) and decreased EPS by \$0.55 (\$47.3 million divided by 86.4 million shares).



RECONCILIATION OF NON-GAAP FINANCIAL MEASURES

Covance Adjusted Operating Income

(In millions, except per share data)

	Yea	r Ended
Adjusted Operating Income	December 31, 2014	
Operating income	\$	234.8
Restructuring costs and transaction related expenses $^{(1)}$		17.1
Asset impairments ⁽¹⁾		52.6
Adjusted operating income	\$	304.4

(1) During 2014, Covance incurred restructuring and transaction related expenses of \$17.1 million. The charges included \$7.6 million in restructuring costs, \$5.5 million in other cost reduction actions and \$4.0 million in transaction related expenses. In addition to these restructuring charges and other cost reduction actions, Covance recorded asset impairment charges totaling \$52.6 million relating to its Chandler, Arizona and Basel, Switzerland facilities and to land owned in Shanghai, China.

